Decitabine (NSC 127716)

Name: Decitabine (NSC 127716)
Brand: Selleck Chemicals
SKU: S1200
Rating: 5 (97 reviews)

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

97 publications

Decitabine (NSC 127716) Chemical Structure

CAS No. 2353-33-5

Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Selleck's Decitabine (NSC 127716) has been cited by 97 publications

Nat Biotechnol, 2019, 10.1038/s41587-019-0372-z

PubMed: 31873215 ( click the link to review the publication )

Nat Med, 2019, 25(7):1073-1081

PubMed: 31270502 ( click the link to review the publication )

Cancer Discov, 2019, 9(1):34-45

PubMed: 30297358 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):906-921

PubMed: 30537513 ( click the link to review the publication )

Cancer Lett, 2021, 507:26-38

PubMed: 33713739 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):90

PubMed: 33941774 ( click the link to review the publication )

Sci Rep, 2021, 11(1):2424

PubMed: 33510302 ( click the link to review the publication )

Life Sci, 2021, S0024-3205(21)00538-5

PubMed: 33932446 ( click the link to review the publication )

Biotechnol Lett, 2021, 10.1007/s10529-021-03112-2

PubMed: 33788127 ( click the link to review the publication )

Nat Commun, 2020, 6;11(1):740

PubMed: 32029739 ( click the link to review the publication )

Oncogene, 2020, 11

PubMed: 32393833 ( click the link to review the publication )

PLoS Genet, 2020, 16(11):e1009159

PubMed: 33175846 ( click the link to review the publication )

J Cancer, 2020, 28;11(10):2874-2886

PubMed: 32226505 ( click the link to review the publication )

Cancer Sci, 2020, 112(1):133-143

PubMed: 33067904 ( click the link to review the publication )

Oncogenesis, 2020, 13;9(5):48

PubMed: 32404892 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Int J Oncol, 2020, 56(6):1429-1441

PubMed: 32236593 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

JCI Insight, 2020, 5(11):e137569

PubMed: 32493845 ( click the link to review the publication )
Sci Rep, 2020, 10(1):11396

PubMed: 32647280 ( click the link to review the publication )

Clin Sci (Lond), 2020, 134(2):273-287

PubMed: 31957803 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30632-7

PubMed: 33253790 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Genet Test Mol Biomarkers, 2020, 24(7):399-408

PubMed: 32551898 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:6665-6677

PubMed: 32801900 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2020, 10.1111/1440-1681.13390

PubMed: 32754907 ( click the link to review the publication )

Am J Transl Res, 2020, 12(7):3461-3475

PubMed: 32774712 ( click the link to review the publication )

Mol Ther Oncolytics, 2020, 18:282-294

PubMed: 32728616 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4155-4167

PubMed: 30952643 ( click the link to review the publication )

Theranostics, 2019, 9(9):2424-2438

PubMed: 31131045 ( click the link to review the publication )

Theranostics, 2019, 9(21):6175-6190

PubMed: 31534544 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2761-2774

PubMed: 30877105 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.118.224048

PubMed: 30796167 ( click the link to review the publication )

PLoS Pathog, 2019, 15(1):e1007578

PubMed: 30699189 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12849

PubMed: 31758842 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:51

PubMed: 31815008 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(8):14040-14049

PubMed: 30623427 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Biomed Pharmacother, 2019, 112:108699

PubMed: 30970511 ( click the link to review the publication )
Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

Life Sci, 2019, 218:241-252

PubMed: 30586565 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):202

PubMed: 30841886 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.06.097

PubMed: 31277942 ( click the link to review the publication )

Appl Health Econ Health Policy, 2019, 17(6):827-839

PubMed: 31392669 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04892-7

PubMed: 31147860 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16970

PubMed: 31740746 ( click the link to review the publication )

Toxicol Lett, 2019, 301:98-107

PubMed: 30481581 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1007-1018

PubMed: 30431129 ( click the link to review the publication )

Dis Markers, 2019, 2019:9175215

PubMed: 31558918 ( click the link to review the publication )

Mol Psychiatry, 2019, 10.1038/s41380-019-0588-9

PubMed: 31745236 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3164

PubMed: 30089774 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Leukemia, 2018, 32(4):900-910

PubMed: 29249821 ( click the link to review the publication )

Theranostics, 2018, 8(16):4520-4534

PubMed: 30214636 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

Oncoimmunology, 2018, 7(10):e1484981

PubMed: 30288346 ( click the link to review the publication )

J Gastroenterol, 2018, 53(1):71-83

PubMed: 28315004 ( click the link to review the publication )

J Cancer, 2018, 9(16):2807-2816

PubMed: 30123349 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):696-706

PubMed: 29453320 ( click the link to review the publication )

Antimicrob Agents Chemother, 2018, 62(9)

PubMed: 29914957 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):237-246

PubMed: 29058035 ( click the link to review the publication )
Biomed Pharmacother, 2018, 104:204-210

PubMed: 29772441 ( click the link to review the publication )

Leuk Res, 2018, 64:34-41

PubMed: 29175379 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2304-2314

PubMed: 28729399 ( click the link to review the publication )

Br J Haematol, 2017, 10.1111/bjh.14707

PubMed: 28439875 ( click the link to review the publication )

Sci Rep, 2017, 7:40762

PubMed: 28094306 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2017, 143(11):2189-2200

PubMed: 28730284 ( click the link to review the publication )

Am J Transl Res, 2017, 9(2):454-465

PubMed: 28337274 ( click the link to review the publication )

Alcohol, 2017, 60:95-101

PubMed: 28433417 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56802-56815

PubMed: 28915632 ( click the link to review the publication )

Oncotarget, 2017, 8(51):89182-89193

PubMed: 29179510 ( click the link to review the publication )

Nat Commun, 2016, 7:11040

PubMed: 27010513 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015, 75(15):2987-98

PubMed: 26122843 ( click the link to review the publication )

J Immunol, 2015, 10.4049/jimmunol.1403196

PubMed: 25825452 ( click the link to review the publication )

Cell Cycle, 2015, 10.1080/15384101.2015.1044174

PubMed: 25946202 ( click the link to review the publication )

Oncol Lett, 2015, 9(4):1691-1698

PubMed: 25789025 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(9):1030-41

PubMed: 26056145 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):536-46

PubMed: 24704162 ( click the link to review the publication )

Leuk Res, 2014, 38(3):402-10

PubMed: 24484870 ( click the link to review the publication )
Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methylation ^[1]
(HL-60, KG1a cells)

In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. ^[1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [³H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Eca109	NVHLOnU5TnWwY4Tpc44hSXO\|YYm=	MXSwMlXDqM7:TR?=	M4XwPFI1KGh?	MWP3ZZRmeg>?	NFT0Z\|Bud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>?	NF\oXJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN\|A5Oid-MkWxNlMxQDJ:L3G+
Eca109	NH3SSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LldFAvPS9{LkWvOUDPxE1?	NHTDWG4zPC92OD:3NkBp	M3zwUJdifGW{	Mki5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?=	NUDXU4F1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109	NVnweFY2TnWwY4Tpc44hSXO\|YYm=	MmTYNE42yqEQvF2=	NGjzWJE3NzF{L{K0JIg>	MlnZe4F1\XJ?	Mn3ObY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?=	MmGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109	MlraSpVv[3Srb36gRZN{[Xl?	MYqwMlXDqM7:TR?=	MYCyOEBp	NU\pWmVNf2G2ZYK=	MVPpcohq[mm2czDj[YxtKGmwdnHzbY9v	NWHzeJVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109	M4e0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;DO\|AvPcLizszN	NVLlUIQ1OjRiaB?=	M4DheZdifGW{	NUXJT3BIcW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109	MV7GeY5kfGmxbjDBd5NigQ>?	M{DDeFAvPS9zIN88US=>	NWqyd21LOjRiaB?=	MmDYe4F1\XJ?	M2XJfYRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ?	MljOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
SW1116	M{PsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzFepcxNjVxMT:yM\|Uh\|ryP	M3jiTFQ5KGh?	NWLyUpgzTE2VTx?=	NWDiW2lV\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>?	M2fQdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
LOVO	MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XwRlAvPS9zL{KvOUDPxE1?	MUS0PEBp	M1KyR2ROW09?	NXvGeWt3\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>?	NGPwTmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O\|QzQDZ:L3G+
SW1116	MXfGeY5kfGmxbjDBd5NigQ>?	M{DZNVExKM7:TR?=	M4Th[lQ5KGh?	NV:3eWJjTE2VTx?=	M{HJU4lv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO	MlLRSpVv[3Srb36gRZN{[Xl?	NXvnUmhCOTBizszN	MXO0PEBp	NWD4S3N[TE2VTx?=	MmTWbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm\|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
SW1116	MmDkRZBweHSxc3nzJGF{e2G7	NXvwS\|FVOTBizszN	M4nUXVQ5KGh?	MnvOSG1UVw>?	M3PVZYVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO	NFvEOnhCeG:ydH;zbZMhSXO\|YYm=	MWCxNEDPxE1?	MoLsOFghcA>?	NH20SWxFVVOR	M3zpdoVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
RPMI-8226	NHPtSlFCeG:ydH;zbZMhSXO\|YYm=	M{LLUlEwOiEQvF2=	M3f3b\|Q5Nzd{L{m2JIg>	MofhSG1UVw>?	NV3NVm1bcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|M{GwPEc,OjR6M{OxNFg9N2F-
OPM-2	MlrBRZBweHSxc3nzJGF{e2G7	NVjqTFdXOS9{IN88US=>	MXu3Nk86Pi9zMkCgbC=>	MnTrSG1UVw>?	M3W4XYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	M3\hc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN\|ExQDxxYU6=
JJN3	MlfTRZBweHSxc3nzJGF{e2G7	MYiwMlUwOSEQvF2=	NXzLW4o6OjRxNEigbC=>	MVnEUXNQ	Mmf5bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M3LNVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN\|ExQDxxYU6=
NCI-H929	M3\pZ2Fxd3C2b4Ppd{BCe3OjeR?=	M1S4flEwOiEQvF2=	NFGxSnk4Oi97Nj:xNlAhcA>?	MlLuSG1UVw>?	NEPCOlBqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NIGwcXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN\|ExQCd-MkS4N\|MyODh:L3G+
RPMI-8226	NV\rR\|I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDiNU8zKM7:TR?=	M3fxOlI1NzR6L{eyJIg>	M3PU[mROW09?	M3nFNYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	NX\3WnhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|MyODhpPkK0PFM{OTB6PD;hQi=>
OPM-2	Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXSxM\|Ih\|ryP	NWj6OIFqOjRxNEivO\|IhcA>?	NWjWXZZuTE2VTx?=	NYrVeHl{[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|M{GwPEc,OjR6M{OxNFg9N2F-
JJN3	NXn1OHlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVewMlUwOSEQvF2=	NHvwNlQzPC92OD:3NkBp	MX3EUXNQ	NE\JUFVi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|M{GwPEc,OjR6M{OxNFg9N2F-
NCI-H929	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\qNU8zKM7:TR?=	NEfyUnozPC92OD:3NkBp	MlXaSG1UVw>?	MWjh[oZm[3S\|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|M{GwPEc,OjR6M{OxNFg9N2F-
HeLa	NGro[llMcW6jc3WgRZN{[Xl?				NInLNIdMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy	MlTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OECwPVgoRjJ2N{iwNFk5RC:jPh?=
HeLa	MYnLbY5ie2ViQYPzZZk>				MUDLbV02NjZiwsGgNE42KM7:TTDmc5IhcEWQVEK=	NHLJfHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
HeLa	M1:yOWtqdmG\|ZTDBd5NigQ>?				NEjFdmVMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy	NVzoXIJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O\|gxODl6PD;hQi=>
HeLa	M2XxOWtqdmG\|ZTDBd5NigQ>?				M3HuR2tqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM>	M3OwTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
NB4	NH:y[mpHfW6ldHnvckBCe3OjeR?=	MnHHNk42NzVxNz61M\|ExKM7:TR?=	MknCNlQhcA>?	NWHqbopKTE2VTx?=	MWnpcoNz\WG\|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh	MmjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OES4O\|AoRjJ2NEi0PFcxRC:jPh?=
CD4+ CD25− T	MXrGeY5kfGmxbjDBd5NigQ>?	NXTVPFRpOS93IN88US=>			NUjr[3p5emWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w	M3HGZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe2N\|YxLz5{NES3OlM3ODxxYU6=
BV-173	NXvoVpB3SXCxcITvd4l{KEG\|c3H5	MYOwMlI2NzBwNT:wMlc2NzFizszN	M136eVQ5Nzd{L{m2JIg>	MYRCpHBDWw>?	MkD3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	NFfReIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
ML-1	NWnpToI2SXCxcITvd4l{KEG\|c3H5	M1Hwc\|AvOjVxMD61M\|AvPzVxMTFOwG0>	NV;zeWd2PDhxN{KvPVYhcA>?	MkXpxsBRSlN?	NEfVNJZqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	NUfVNJZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF\|PD;hQi=>
HL-60	M3\rVGFxd3C2b4Ppd{BCe3OjeR?=	MkDONE4zPS9yLkWvNE44PS9zIN88US=>	NF3he2w1QC95Mj:5OkBp	MXJCpHBDWw>?	MUnpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	M33ZbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN\|YyOzxxYU6=
KG-1a	NVX4RotNSXCxcITvd4l{KEG\|c3H5	M3PX[\|AvOjVxMD61M\|AvPzVxMTFOwG0>	MVm0PE84Oi97NjDo	M2ThPeKhWEKV	Mn;vbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
BV-173	M3LiPWZ2dmO2aX;uJGF{e2G7	MlrLNlUxNzVyMH7N	NILoO4M1QCCq	NXrTRnNCyqCSQmO=	MlTnbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	NFPtXmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
CEM	MXzGeY5kfGmxbjDBd5NigQ>?	NYj0[G5XOjVyL{WwNI5O	MXK0PEBp	NVfpNHh1yqCSQmO=	M3fDe4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W\|dHHpcoVlKFKRUzDpcoNz\WG\|ZR?=	NWTIcXhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF\|PD;hQi=>
HL-60	M1XKdWZ2dmO2aX;uJGF{e2G7	NV;idHZQOjVyL{WwNI5O	MmHoOFghcA>?	NXTEXWI5yqCSQmO=	MXvpcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	NULjdoRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF\|PD;hQi=>
ML-1	NG\XeZpHfW6ldHnvckBCe3OjeR?=	MXiyOVAwPTBybl2=	MlrYOFghcA>?	MX1CpHBDWw>?	NGO2eG9qdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W=	M4D1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN\|YyOzxxYU6=
DLD-1	MUTGeY5kfGmxbjDBd5NigQ>?	NYnPe4lPOjVyL{WwNI5O	MlLJOFghcA>?	NVrvcZplyqCSQmO=	NHn4RoVldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	M2Ho[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN\|YyOzxxYU6=
HCT-116	NV;DSHBMTnWwY4Tpc44hSXO\|YYm=	Mlu5NlUxNzVyMH7N	MWi0PEBp	NUTBXnpvyqCSQmO=	MYnkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
U937-A/E-9/14/18	MV7BdI9xfG:\|aYOgRZN{[Xl?	NGXS[GoxNjBzL{CuNU8yNzFyIN88US=>	NFrDVGQ1QCCq		MW\pcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NF;oNpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOwNFQ2Pid-MkSzNFA1PTZ:L3G+
HT29	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MU[3NkBp		M2foPWlEPTB;MUSwNOKyOTd7IN88US=>	MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{KwOlEoRjJ2MUeyNFYyRC:jPh?=
SW48	NIjTVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2\TdlczKGh?		NYfMN4RpUUN3ME2xOU4zyrF4LkKg{txO	NVzaZlVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|IxPjFpPkK0NVczODZzPD;hQi=>
HCT116	NITDTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYnVNnMyPzJiaB?=		M1nOcWlEPTB;MT63xtExNjRizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5MkC2NUc,OjRzN{KwOlE9N2F-
HepG2	NGPHTJhHfW6ldHnvckBCe3OjeR?=	NY[yT3NSOC53L{Gg{txO	NYHqdpg{OjRiaB?=	MY\EUXNQ	NEXBcIp2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?=	MmD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O\|QoRjJ2MUS2PFc1RC:jPh?=
LS174T	MXjGeY5kfGmxbjDBd5NigQ>?	MnXHNE42NzFizszN	NEXVZXkzPCCq	MW\EUXNQ	MnHEcIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO=	M2G5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
HepG2	Ml\uRZBweHSxc3nzJGF{e2G7	NVjqToM3OS9zMD:xNFAh\|ryP	MnX4O{Bl	NI\OR2VFVVOR	Mn7PbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NEHNcJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0Olg4PCd-MkSxOFY5PzR:L3G+
LS174T	NF7iUWVCeG:ydH;zbZMhSXO\|YYm=	NYrQeJNqOS9zMD:xNFAh\|ryP	NXLnVHdsPyCm	MoDmSG1UVw>?	M2\Wd4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M1qwVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
QBC-939	NIHtO4pCeG:ydH;zbZMhSXO\|YYm=	M3jaWlEwOTBxMUCwJO69VQ>?	MWC3JIQ>	NIX2OVJFVVOR	MYLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O\|Q9N2F-
U251	NH\XTmpCeG:ydH;zbZMhSXO\|YYm=	NYjrcJkxOS9zMD:xNFAh\|ryP	NF7qbWU4KGR?	NHSyTYVFVVOR	MVnpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MlX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O\|QoRjJ2MUS2PFc1RC:jPh?=
HL-60	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHFNUDPxE1?	Mmi3OFghcA>?		NGnmTXNqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?=	NYDNUZhKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFA{OjRpPkK0NFAxOzJ2PD;hQi=>
MDA‑MB‑453	NVLhNoxSTnWwY4Tpc44hSXO\|YYm=	M3SxW\|AvOi9zIN88US=>	MUG3NkBp		NXXmclU4[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NEKyPEc,OjN6NESyNlg9N2F-
HCC1569	Mn7USpVv[3Srb36gRZN{[Xl?	NWjVVZVTOC5{L{Gg{txO	NFHodYI4OiCq		M{SzbINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=>	MmP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESyNlgoRjJ\|OES0NlI5RC:jPh?=
BT‑474	NV7kfoFPTnWwY4Tpc44hSXO\|YYm=	MVOwMlIwOSEQvF2=	MVK3NkBp		MnXlZ4F2e2W\|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg	NGPQ[FM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFIzQCd-MkO4OFQzOjh:L3G+
AGS	MYDBdI9xfG:\|aYOgRZN{[Xl?	MUG1M\|ExNzJyL{WwJO69VQ>?	MoHKOFjDqGkEoB?=	M13PN2ROW09?	M1jkTIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh	MlW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OEK3PFQoRjJ\|NUiyO\|g1RC:jPh?=
A549	NX:1VGJuSXCxcITvd4l{KEG\|c3H5	NXnpNGQyPS9zMD:yNE82OCEQvF2=	MkLzOFjDqGkEoB?=	NYLF[JBUTE2VTx?=	NH3sO4RqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>?	M1rEV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUiyO\|g1Lz5{M{W4Nlc5PDxxYU6=
AGS	MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYK1M\|ExNzJyL{WwJO69VQ>?	MUC0POKhcMLi	MnL4SG1UVw>?	MVPpcoR2[2W\|IFeyM20heGijc3WgZZJz\XO2wrC=	NES5bGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W4Nlc5PCd-MkO1PFI4QDR:L3G+
Kasumi-1	M4\QZWFxd3C2b4Ppd{BCe3OjeR?=	NVvXWoREOC53IN88US=>	NVjDNItiPDkEoHlCpC=>		NV75fpp[\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7M{O0PEc,OjN2OUOzOFg9N2F-
OCI-AML3	MlPRRZBweHSxc3nzJGF{e2G7	MWqyMlUh\|ryP	MYG0POKhcMLi		NGH3dGtl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=>	M4DoSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEmzN\|Q5Lz5{M{S5N\|M1QDxxYU6=
MV4-11	MoS1RZBweHSxc3nzJGF{e2G7	M3PjXFIvPSEQvF2=	Ml;lOFjDqGkEoB?=		NVHRUnUz\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M>	NWLUS49LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM{PDhpPkKzOFk{OzR6PD;hQi=>
NK	MYjDfZRwfG:6aYT5JGF{e2G7	MlrTNE4xOi1{MDFOwG0>	NVq4[I5sPSCm		MmDl[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26\|ZTDjeZJ3\Q>?	M1;HblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{K4NFg5Lz5{M{OyPFA5QDxxYU6=
NK	MUTBdI9xfG:\|aYOgRZN{[Xl?	NEjjTpAxNjB{LUKwJO69VQ>?	MnnhOUBl		M1;qVYRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>?	NFO5dGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
NK	M4n3eGZ2dmO2aX;uJGF{e2G7	M2rDSFAvODFvMkCg{txO	NFm5O202KGR?		NXzpNpg{[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>?	NFrmb4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
MOLT4/DNR	MoPzSpVv[3Srb36gRZN{[Xl?	MXq1JO69VQ>?	NG\5UIE1KGR?		NIrIcW1z\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>?	NYLaTIFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlA2PzBpPkKzNFYxPTdyPD;hQi=>
Jurkat/DOX	M1;VNGZ2dmO2aX;uJGF{e2G7	MlnlOUDPxE1?	NGXrUVU1KGR?		MofIdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44>	NEfNWZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NFU4OCd-MkOwOlA2PzB:L3G+
MOLT4/DNR	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPBemg2KM7:TR?=	NWnMdlhTPCCm		MoTwdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC\|ZX7zbZRqfmm2eR?=	M{HQ[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
Jurkat/DOX	NX3oZ4VHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXv6TXhNPSEQvF2=	M3TBcVQh\A>?		NXG0WnVsemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=>	M3HQcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
ccRCC	M4rRbmFxd3C2b4Ppd{BCe3OjeR?=	MnjCNE4xOS1zMN88US=>	M1zESFczKGh?	MlPUSG1UVw>?	M4ju[YhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25?	NGj4PWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
TNBC	MUDBdI9xfG:\|aYOgRZN{[Xl?	NHuzdHYxNjBzLUGw{txO	M1H6dFczKGh?	M{i1WWROW09?	MXjoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
A498	MVLBdI9xfG:\|aYOgRZN{[Xl?	NXPRZ45pOC5yMT2xNO69VQ>?	NIn3WIg4OiCq	MYrEUXNQ	NVrhdXRmcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>?	NEjz[Zc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
KIJ265T	NIKz[pBCeG:ydH;zbZMhSXO\|YYm=	NWnZOnF[OC5yMT2xNO69VQ>?	MYK3NkBp	MV\EUXNQ	MYXpcoR2[2W\|IIP5coVz\2m\|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu	NEKwSGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
MDA-231	MlvCRZBweHSxc3nzJGF{e2G7	MUSwMlAyNTFyzszN	NHW0ZZM4OiCq	MWfEUXNQ	Mo\PbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=>	M3nQXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
BT-20	MlnCRZBweHSxc3nzJGF{e2G7	M2XKVlAvODFvMUFOwG0>	NF;KbI84OiCq	NUPBR\|JwTE2VTx?=	MYnpcoR2[2W\|IIP5coVz\2m\|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu	NV;2WYVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
U937	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DI[\|UuOjBizszN	NHLmd3AzPC92OD:3NkBp		NV\PS2JRcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	NUi5TXZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO\|Y4ODJzPD;hQi=>
HL60	M4LsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUW1MVIxKM7:TR?=	M{PaVVI1NzR6L{eyJIg>		MVfpcoR2[2W\|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	M3nw[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{[3NFIyLz5{Mke2O\|AzOTxxYU6=
U937	MV7BdI9xfG:\|aYOgRZN{[Xl?	M3H2O\|E2KM7:TR?=	NXrUVJJwOjRxNEivO\|IhcA>?		NUHx[FFDcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NYizcHFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO\|Y4ODJzPD;hQi=>
HL60	NEm4N2JCeG:ydH;zbZMhSXO\|YYm=	M3LPb\|E2KM7:TR?=	MkTmNlQwPDhxN{KgbC=>		MVLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
LS411N	M{XEUmFxd3C2b4Ppd{BCe3OjeR?=	NH;OOGkxNjVizszN	NGnrVo84OiCq		NVHGWoN4cW6lcnXhd4V{KE[jczDtVm5CKGyndnXs	MnXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2NkG2PVUoRjJ{NE[xOlk2RC:jPh?=
MDA-MB-231	MUTBdI9xfG:\|aYOgRZN{[Xl?	MmLGNVAh\|ryP	MXq0PEBp		NV;ad4ViemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh6N{[5O{c,OjF6OEe2PVc9N2F-
MCF-7	NYr6OFNySXCxcITvd4l{KEG\|c3H5	Mon5NVAh\|ryP	M4jEZ\|Q5KGh?		M1HXZpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NFO1fY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi4O\|Y6Pyd-MkG4PFc3QTd:L3G+
A375	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;JNE42KM7:TR?=	NGPFSoQyNzVxODDk		NFfVNmhqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL1	NWSz[YcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHOxU4QxNjVizszN	M3PHbVEwPS96IHS=		M4rkdolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	M2XGU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
SKMEL3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\SXFAvPSEQvF2=	NYnneHh2OS93L{ig[C=>		MUXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	MkfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
SKMEL28	NGDafWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;rcGs3OC53IN88US=>	MVSxM\|UwQCCm		NXHYNVA4cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	MnH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
MeWo	NYDZcGR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXVNE42KM7:TR?=	NX7kUWRmOS93L{ig[C=>		M1LDN4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	MlnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
B16	M1fW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX2wMlUh\|ryP	NF;qcnEyNzVxODDk		MkGzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	MnvsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
Ly 1	M{LqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MojHNlQhcA>?		NW\zcFg{UUN3ME23MlMh\|ryP	NVGy[W1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
Ly 7	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUf0T5N7OjRiaB?=		NH7DO4VKSzVyPUGwMlch\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6	NWjKfoczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmrXNlQhcA>?		M2H2dmlEPTExvK6yNEDPxE1?	NWHBXHB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
Ly 10	MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2OxWVI1KGh?		NYDB[Gs3UUN3MP-8olIxKM7:TR?=	MljqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
RIVA	NUL5VFZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV:yOEBp		MnL5TWM2OO,:nkKwJO69VQ>?	M3zsR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2	NX;lOHVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXiyOEBp		M1;lU2lEPTExvK6yNEDPxE1?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmXkOFghcA>?		M3;MS2lEPTB;MD6zOEDPxE1?	M3:4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7	M2PIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGm2N5g1QCCq		NHPMPHlKSzVyPUCuNFI2KM7:TR?=	NF7ufJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O\|IxPDl:L3G+
Su-DHL6	Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH3GfJc1QCCq		NWHCTXNZUUN3MP-8olIxKM7:TR?=	MlLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 10	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2XlN\|Q5KGh?		MWjJR\|UxRTFwODFOwG0>	M3P1Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA	NV7zcZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2jFR\|Q5KGh?		MXXJR\|Ux97zgMkCg{txO	M{PEXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2	MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFSyWoo1QCCq		NEX1dVRKSzVyPUG3MlQh\|ryP	NWHKVYJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
Ly 1	M17mN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3PTPFczKGh?		MmLQTWM2OD1yLkCxJO69VQ>?	M3nMe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXT4WpR7PzJiaB?=		NXXDcXRHUUN3ME2wMlAyQCEQvF2=	NX;j[JBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
Su-DHL6	NFvOe21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnjzO\|IhcA>?		NF;xUlBKSzVyPUGuOkDPxE1?	NE\tU5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O\|IxPDl:L3G+
Ly 10	NIC0SlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M37SWFczKGh?		NHHVNmNKSzVyPUGuNkDPxE1?	Mnn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
RIVA	M3vjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV[3NkBp		MVTJR\|Ux97zgMkCg{txO	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2	NHq4dnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEP4XpA4OiCq		NX\0O4pXUUN3ME2xNU4zKM7:TR?=	M4jWNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
U373-MAGI	Mmn2RY51cX[rcnHsJIF{e2G7	NGjudXUxNjJ3IITvJFghfU1?	M{HEVFIhfG9iN{KgbJJ{		NGOxV41CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBXW1ZvRzDwd4V2\G:2eYDl[EBJUVZvMTDOUFQuOyCrbn\lZ5Rm\CCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHU2NWejZzDs[ZZmdCCjdDCwMlI2KHSxIEigeW0h[W[2ZYKgNkB1dyB5MjDodpMh[nlicWDDVkBu\XSqb3S=	NWDNcIFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
U373-MAGI	MWPBcpRqfmm{YXygZZN{[Xl?	MlziNE4zPSC2bzC4JJVO	MljyNkB1dyB5MjDodpM>		NXvX[YJFSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBo[WdibHX2[Ywh[XRiMD6yOUB1dyB6IIXNJIFnfGW{IEKgeI8hPzJiaILzJIJ6KHGSQ2KgcYV1cG:m	M{juZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO\|I3ODxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Survivin / Bcl-2 / p53 / c-Myc / DNMT1; PubMed: 26384351 Oncotarget HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells. p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; PubMed: 25762617 Oncotarget Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations. phospho-p38 / p38 / phospho-NFκB / NFκB; PubMed: 26617834 Int J Clin Exp Pathol Decitabine suppressed the phosphorylation of p38 and NF-κB. p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; PubMed: 26692933 Am J Transl Res DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments. E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; PubMed: 28152502 Oncotarget The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.	26384351 25762617 26617834 26692933 28152502
Immunofluorescence	DNMT1; PubMed: 21303982 Cancer Res Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain). E-cadherin / MMP-9; PubMed: 28152502 Oncotarget Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC.	21303982 28152502
Growth inhibition assay	Cell viability; PubMed: 26384351 Oncotarget Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.	26384351

In vivo

In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse DNA synthesis assay : The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [³H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:^[1]	- Collapse Cell lines: HL-60 and KG1a Concentrations: 0-500 nM Incubation Time: 96 hours Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice. Dosages: ≤2.5 mg/kg Administration: Administered via i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	45 mg/mL (197.18 mM)
	Water	10 mg/mL (43.81 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Decitabine (NSC 127716) SDF

Molecular Weight	228.21
Formula	C₈H₁₂N₄O₄
CAS No.	2353-33-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR
Smiles	C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04854889	Recruiting	Drug: Decitabine	Refractory Aplastic Anemia	Institute of Hematology & Blood Diseases Hospital	April 22 2021	Phase 2
NCT04086238	Completed	Drug: Decitabine	Healthy	EpiDestiny Inc.	October 8 2019	Phase 1
NCT04113616	Recruiting	Drug: KRT-232\|Drug: Cytarabine\|Drug: Decitabine	Acute Myeloid Leukemia (AML)\|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN)	Kartos Therapeutics Inc.	September 25 2019	Phase 1\|Phase 2
NCT03875287	Recruiting	Drug: Decitabine\|Drug: Cedazuridine	Solid Tumor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Astex Pharmaceuticals Inc.	April 17 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?
Answer:
S1200 is R form

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine (NSC 127716)